Cargando…

IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses

Despite the great impact on long-term survival of some cancer patients, the immune checkpoint blockade (ICB) therapy is limited by its low response rates for most cancers. There is a pressing need for novel combination immunotherapies that overcome the resistance to current ICB therapies. Cytokines...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qu, Qiuxia, Zhai, Zhiwei, Xu, Jieni, Li, Song, Chen, Cheng, Lu, Binfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174717/ https://www.ncbi.nlm.nih.gov/pubmed/32351508 http://dx.doi.org/10.3389/fimmu.2020.00634

Ejemplares similares

(64)Cu-DOTA-Anti-CTLA-4 mAb Enabled PET Visualization of CTLA-4 on the T-Cell Infiltrating Tumor Tissues
por: Higashikawa, Kei, et al.
Publicado: (2014)

Combined IL-2 Immunocomplex and Anti-IL-5 mAb Treatment Expands Foxp3(+) Treg Cells in the Absence of Eosinophilia and Ameliorates Experimental Colitis
por: Abo, Hirohito, et al.
Publicado: (2019)

SEPPA-mAb: spatial epitope prediction of protein antigens for mAbs
por: Qiu, Tianyi, et al.
Publicado: (2023)

New Insights on the Role of Anti-PD-L1 and Anti-CTLA-4 mAbs on Different Lymphocytes Subpopulations in TNBC
por: Lembo, Rosa Rapuano, et al.
Publicado: (2022)

IL-36β Promotes CD8(+) T Cell Activation and Antitumor Immune Responses by Activating mTORC1
por: Zhao, Xin, et al.
Publicado: (2019)

Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells
por: Passariello, Margherita, et al.
Publicado: (2020)

Therapeutic potential of an anti-CCR9 mAb evidenced in xenografts of human CCR9(+) tumors
por: Santamaria, Silvia, et al.
Publicado: (2022)

P3 mAb: An Immunogenic Anti-NeuGcGM3 Antibody with Unusual Immunoregulatory Properties
por: Martínez, Darel, et al.
Publicado: (2012)

Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB
por: Manso, Taciana, et al.
Publicado: (2023)

State of the art in anti-cancer mAbs
por: Chiavenna, S. M., et al.
Publicado: (2017)

Population pharmacokinetic models of anti-PD-1 mAbs in patients with multiple tumor types: A systematic review
por: Shang, Jingyuan, et al.
Publicado: (2022)

Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb
por: Bolaños-Mateo, Elixabet, et al.
Publicado: (2014)

Will a mAb-Based Immunotherapy Directed against Cancer Stem Cells Be Feasible?
por: Santamaria, Silvia, et al.
Publicado: (2017)

Modulating the tumor microenvironment improves antitumor effect of anti-PD-L1 mAb in breast cancer
por: Li, Xiuying, et al.
Publicado: (2023)

Safety and Immunological Evaluation of Interleukin-21 Plus Anti-α4β7 mAb Combination Therapy in Rhesus Macaques
por: Pino, Maria, et al.
Publicado: (2020)

Fc Binding by FcγRIIa Is Essential for Cellular Activation by the Anti-FcγRIIa mAbs 8.26 and 8.2
por: Wines, Bruce D., et al.
Publicado: (2021)

Anti-CD40 predominates over anti-CTLA-4 to provide enhanced antitumor response of DC-CIK cells in renal cell carcinoma
por: Zhang, Ying, et al.
Publicado: (2022)

Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases
por: Menzella, Francesco, et al.
Publicado: (2015)

Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs
por: Fusco, Marnie L., et al.
Publicado: (2015)

Profile of Anti-IL-5 mAb Mepolizumab in the Treatment of Severe Refractory Asthma and Hypereosinophilic Diseases [Corrigendum]
Publicado: (2021)

The Different Colors of mAbs in Solution
por: Ambrogelly, Alexandre
Publicado: (2021)

Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors
por: Demerlé, Clémence, et al.
Publicado: (2023)

Correction: Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs
por: Fusco, Marnie L., et al.
Publicado: (2015)

Screening and antitumor effect of an anti-CTLA-4 nanobody
por: Wan, Ruirong, et al.
Publicado: (2018)

Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma
por: Kroesen, Michiel, et al.
Publicado: (2016)

The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs
por: Golay, Josée, et al.
Publicado: (2020)

A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti–PD-1 mAb, in patients with advanced or metastatic solid tumors
por: Huang, Zhiyu, et al.
Publicado: (2023)

Development of Lentiviral Vectors Pseudotyped With Influenza B Hemagglutinins: Application in Vaccine Immunogenicity, mAb Potency, and Sero-Surveillance Studies
por: Ferrara, Francesca, et al.
Publicado: (2021)

Effect of in vivo Hydroxychloroquine and ex vivo Anti-BDCA2 mAb Treatment on pDC IFNα Production From Patients Affected With Cutaneous Lupus Erythematosus
por: Gardet, Agnes, et al.
Publicado: (2019)

Metformin Enhances the Therapy Effects of Anti-IGF-1R mAb Figitumumab to NSCLC
por: Cao, Hongxin, et al.
Publicado: (2016)

IL-2/JES6-1 mAb complexes dramatically increase sensitivity to LPS through IFN-γ production by CD25(+)Foxp3(-) T cells
por: Tomala, Jakub, et al.
Publicado: (2021)

Ex Vivo Generation of Donor Antigen-Specific Immunomodulatory Cells: A Comparison Study of Anti-CD80/86 mAbs and CTLA4-lg Costimulatory Blockade
por: Watanabe, M., et al.
Publicado: (2018)

Rational strategies for enhancing mAb binding to SARS-CoV-2 variants through CDR diversification and antibody-escape prediction
por: Shah, Masaud, et al.
Publicado: (2023)

Cellular tools for biosimilar mAb analysis
por: Lindemann, Carsten, et al.
Publicado: (2013)

Evolving trends in mAb production processes
por: Shukla, Abhinav A., et al.
Publicado: (2017)

Plant Recycling for Molecular Biofarming to Produce Recombinant Anti-Cancer mAb
por: Kim, Deuk-Su, et al.
Publicado: (2016)

Expression and in vitro function of anti-cancer mAbs in transgenic Arabidopsis thaliana
por: Song, Ilchan, et al.
Publicado: (2020)

Treatment of Marmoset Intracerebral Hemorrhage with Humanized Anti-HMGB1 mAb
por: Wang, Dengli, et al.
Publicado: (2022)

Anti-CD40 mAb enhanced efficacy of anti-PD1 against osteosarcoma
por: Zhang, Jingzhe, et al.
Publicado: (2019)

Comparison between Internalizing Anti-HER2 mAbs and Non-Internalizing Anti-CEA mAbs in Alpha-Radioimmunotherapy of Small Volume Peritoneal Carcinomatosis Using (2) (1) (2)Pb
por: Boudousq, Vincent, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_bng50nfcm6bc6iulq2jsehmkkh